亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

医学 trk受体 肿瘤科 人口 实体瘤疗效评价标准 内科学 癌症 临床研究阶段 临床试验 受体 神经营养素 环境卫生
作者
Robert Charles Doebele,Alexander Edward Dela Cruz Drilon,Luis G Paz-Ares,Salvatore Siena,Alice Tsang Shaw,Anna F. Farago,Collin Michael Blakely,Takashi Seto,Byoung Chul Cho,Diégo Tosi,Benjamin Besse,Sant P. Chawla,Lyudmila A. Bazhenova,John C. Krauss,Young Kwang Chae,Minal A. Barve,Ignacio Garrido‐Laguna,Stephen V. Liu,Paul Conkling,Thomas John
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:21 (2): 271-282 被引量:1861
标识
DOI:10.1016/s1470-2045(19)30691-6
摘要

Background Entrectinib is a potent inhibitor of tropomyosin receptor kinase (TRK) A, B, and C, which has been shown to have anti-tumour activity against NTRK gene fusion-positive solid tumours, including CNS activity due to its ability to penetrate the blood–brain barrier. We present an integrated efficacy and safety analysis of patients with metastatic or locally advanced solid tumours harbouring oncogenic NTRK1, NTRK2, and NTRK3 gene fusions treated in three ongoing, early-phase trials. Methods An integrated database comprised the pivotal datasets of three, ongoing phase 1 or 2 clinical trials (ALKA-372-001, STARTRK-1, and STARTRK-2), which enrolled patients aged 18 years or older with metastatic or locally advanced NTRK fusion-positive solid tumours who received entrectinib orally at a dose of at least 600 mg once per day in a capsule. All patients had an Eastern Cooperative Oncology Group performance status of 0–2 and could have received previous anti-cancer therapy (except previous TRK inhibitors). The primary endpoints, the proportion of patients with an objective response and median duration of response, were evaluated by blinded independent central review in the efficacy-evaluable population (ie, patients with NTRK fusion-positive solid tumours who were TRK inhibitor-naive and had received at least one dose of entrectinib). Overall safety evaluable population included patients from STARTRK-1, STARTRK-2, ALKA-372-001, and STARTRK-NG (NCT02650401; treating young adult and paediatric patients [aged ≤21 years]), who received at least one dose of entrectinib, regardless of tumour type or gene rearrangement. NTRK fusion-positive safety evaluable population comprised all patients who have received at least one dose of entrectinib regardless of dose or follow-up. These ongoing studies are registered with ClinicalTrials.gov, NCT02097810 (STARTRK-1) and NCT02568267 (STARTRK-2), and EudraCT, 2012–000148–88 (ALKA-372-001). Findings Patients were enrolled in ALKA-372–001 from Oct 26, 2012, to March 27, 2018; in STARTRK-1 from Aug 7, 2014, to May 10, 2018; and in STARTRK-2 from Nov 19, 2015 (enrolment is ongoing). At the data cutoff date for this analysis (May 31, 2018) the efficacy-evaluable population comprised 54 adults with advanced or metastatic NTRK fusion-positive solid tumours comprising ten different tumour types and 19 different histologies. Median follow-up was 12.9 months (IQR 8·77–18·76). 31 (57%; 95% CI 43·2–70·8) of 54 patients had an objective response, of which four (7%) were complete responses and 27 (50%) partial reponses. Median duration of response was 10 months (95% CI 7·1 to not estimable). The most common grade 3 or 4 treatment-related adverse events in both safety populations were increased weight (seven [10%] of 68 patients in the NTRK fusion-positive safety population and in 18 [5%] of 355 patients in the overall safety-evaluable population) and anaemia (8 [12%] and 16 [5%]). The most common serious treatment-related adverse events were nervous system disorders (three [4%] of 68 patients and ten [3%] of 355 patients). No treatment-related deaths occurred. Interpretation Entrectinib induced durable and clinically meaningful responses in patients with NTRK fusion-positive solid tumours, and was well tolerated with a manageable safety profile. These results show that entrectinib is a safe and active treatment option for patients with NTRK fusion-positive solid tumours. These data highlight the need to routinely test for NTRK fusions to broaden the therapeutic options available for patients with NTRK fusion-positive solid tumours. Funding Ignyta/F Hoffmann-La Roche.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
1秒前
2秒前
2秒前
纯情的阁发布了新的文献求助10
3秒前
纯情的阁发布了新的文献求助10
3秒前
纯情的阁发布了新的文献求助10
3秒前
纯情的阁发布了新的文献求助10
3秒前
纯情的阁发布了新的文献求助10
3秒前
4秒前
4秒前
4秒前
清爽的绝山完成签到,获得积分10
6秒前
纯情的阁发布了新的文献求助10
6秒前
纯情的阁发布了新的文献求助10
6秒前
纯情的阁发布了新的文献求助10
6秒前
纯情的阁发布了新的文献求助10
6秒前
纯情的阁发布了新的文献求助10
6秒前
7秒前
8秒前
8秒前
纯情的阁发布了新的文献求助10
10秒前
纯情的阁发布了新的文献求助10
10秒前
纯情的阁发布了新的文献求助10
10秒前
10秒前
纯情的阁发布了新的文献求助10
10秒前
纯情的阁发布了新的文献求助10
10秒前
四氧化三铁完成签到,获得积分10
10秒前
纯情的阁发布了新的文献求助10
13秒前
纯情的阁发布了新的文献求助10
13秒前
纯情的阁发布了新的文献求助10
13秒前
纯情的阁发布了新的文献求助10
13秒前
13秒前
纯情的阁发布了新的文献求助10
13秒前
15秒前
复杂以旋完成签到,获得积分10
15秒前
纯情的阁发布了新的文献求助30
17秒前
纯情的阁发布了新的文献求助10
17秒前
纯情的阁发布了新的文献求助10
17秒前
纯情的阁发布了新的文献求助10
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Analyses de reconnaissances de dettes passées devant les échevins d'Ypres (1249-1291) 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158792
求助须知:如何正确求助?哪些是违规求助? 9554476
关于积分的说明 21719316
捐赠科研通 7748395
什么是DOI,文献DOI怎么找? 3427099
关于科研通互助平台的介绍 2551987
邀请新用户注册赠送积分活动 2471354